Hepatocellular carcinoma patients with undetectable baseline hepatitis B viral DNA may benefit from immunotherapy
The status of HBV DNA exerts an influence on the prognosis of HCC patients undergoing immunotherapy, and this influence is independent of the viral load. HCC patients with undetectable HBV DNA tend to have more favorable short - term survival outcomes. For patients who have received effective antiviral therapy, elevated levels of HBV DNA should not be used as an exclusion criterion for immunotherapy.
Authors
- Yan Jian
- Zhimin Qiu
- Hanzhi Dong
- Lin Zhou (ORCID: https://orcid.org/0000-0002-2549-2721)
- Meijian Wang (ORCID: https://orcid.org/0000-0002-8122-1678)
- Sicong Jiang (ORCID: https://orcid.org/0000-0001-8974-6770)
- Yuan Qiu (ORCID: https://orcid.org/0000-0002-8997-4367)
Institutions
- Jiangxi Provincial Cancer Hospital (CN)
Publication Details
- Journal
- BMC Gastroenterology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.1186/s12876-025-04043-2
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Nanchang University